CD166, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG

Search, find, compare suppliers for anti-CD166, Human antibody, protein, ELISA kits.

Edit 
Antigenic SpecificityCD166, Human
CloneREA442
Host SpeciesRecombinant Human
Reactive Specieshuman
IsotypeIgG1
FormatVio Bright B515 conjugate
Size100 tests in 200 µL
Concentration1:50
ApplicationsFlow cytometry
Reviews / RatingsIf you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
DescriptionCD166 Antibody, anti-human, Vio® Bright B515, REAfinity™. Clone REA442 recognizes the human CD166 antigen, a single-pass type I membrane protein also known as activated leukocyte cell adhesion molecule (ALCAM). CD166, a member of the immunoglobulin superfamily and a ligand for the lymphocyte antigen CD6, mediates homophilic and heterophilic adhesion. It is expressed on activated leukocytes T cells, B cells, monocytes, hematopoietic stem cells (HSCs), metastasizing melanoma, neuronal cells, endothelial cells, hematopoiesis-supporting osteoblastic cell lines, and mesenchymal stem cells (MSCs). CD166 expression is pathologically correlated with aggressive disease in a variety of cancers including melanoma, prostate, breast, ovarian, esophageal, and bladder cancers. It is also a universal functional marker of murine and human HSCs and osteoblasts within the hematopoietic niche and it is involved in modulating HSC-niche interactions and HSC fate. | Additional information: Clone REA442 displays negligible binding to Fc receptors.
Immunogenn/a
Other NamesALCAM, MEMD
Gene, Accession #Gene ID: 214
Catalog #130-126-916
Price$440
Order / More InfoCD166, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Product Specific ReferencesChitteti, B. R. et al. (2014) CD166 regulates human and murine hematopoietic stem cells and the hematopoietic niche. Blood 124 (4): 519-529. | Degen, W. G. et al. (1998) MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule). Am. J. Pathol. 152 (3): 805-813. | Ni, C. et al. (2013) Prognostic value of CD166 expression in cancers of the digestive system: a systematic review and meta-analysis. PLoS One 8 (8): e70958.
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-Straße 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197

macs@miltenyibiotec.de

https://www.miltenyibiotec.com

Profile of MILTENYI BIOTEC B.V. & Co. KG
Return to Antibodies

© 1980 - 2024 Linscott's Directory, Linscott's USA. All rights reserved.